Adelaide Health Technology Assessment, University of Adelaide, Adelaide, Level 9, AHMS Building, North Terrace 5005, South Australia, Australia.
J Inherit Metab Dis. 2019 Jan;42(1):57-65. doi: 10.1002/jimd.12027.
The objective of this research was to determine the effectiveness of enzyme replacement therapy for juvenile-onset Pompe disease (patients aged 2 to 18 years at symptom onset) by systematic review.
A systematic search was conducted according to a protocol designed a priori of bibliographic databases and search engines. Studies selected according to pre-specified criteria were assessed for quality and risk of bias using standardised appraisal tools. Data were reported according to PRISMA conventions (Liberati et al. in PLoS Med 6:e1000100, 2009) and synthesised using GRADE (Guyatt et al. in J Clin Epidemiol 64:380-382, 2011).
Of 2537 titles screened, 1 case series and 16 case reports met the inclusion criteria. No studies reported on the impact of enzyme replacement therapy on the survival of juvenile-onset patients. Low level evidence found that respiratory function may improve or be maintained in the early months of therapy. Improved muscle function in the first 6 to 12 months was also suggested, but results may be confounded by natural development. Patients with less severe baseline status and treated at a younger age showed more response than patients with more severe baseline status, treated as adults.
Interpretation of the findings was hindered by the lack of good quality evidence. The available data suggests that some JOPD patients may benefit in the short term from ERT through improved muscle strength and a reduced need for assisted ventilation. A focus by clinicians on improved and more consistent evidence collection, and use of study designs tailored to rare conditions, would provide more definitive results.
本研究旨在通过系统评价来确定酶替代疗法对青少年起病庞贝病(发病年龄为 2 至 18 岁)的疗效。
根据预先制定的文献数据库和搜索引擎检索方案进行系统检索。根据预先规定的标准选择研究,并使用标准化评估工具评估其质量和偏倚风险。根据 PRISMA 公约(Liberati 等人,PLoS Med 6:e1000100, 2009)报告数据,并使用 GRADE(Guyatt 等人,J Clin Epidemiol 64:380-382, 2011)进行综合。
在筛选出的 2537 篇标题中,有 1 项病例系列研究和 16 项病例报告符合纳入标准。没有研究报告酶替代疗法对青少年起病患者的生存影响。低水平证据表明,在治疗的早期几个月,呼吸功能可能会改善或维持。还提示早期 6 至 12 个月肌肉功能可能改善,但结果可能受到自然发展的影响。基线状态较轻且接受治疗的年龄较小的患者比基线状态较重、成年后接受治疗的患者反应更好。
由于缺乏高质量证据,对研究结果的解释受到阻碍。现有数据表明,一些 JOPD 患者可能会从短期的 ERT 中受益,表现为肌肉力量增强和减少对辅助通气的需求。临床医生关注改善和更一致的证据收集,并使用针对罕见疾病的研究设计,将提供更明确的结果。